InGeneron Extends Series D Financing to $43 Million to Bring Regenerative Cell Therapy into the Clinic

InGeneron, Inc., a clinical stage regenerative medicine and cell therapy company, announced today the extension of its Series D financing by up to $23 million, totaling up to $43 million to be invested in the organization.